Thymogen research: studies, doses and safety

A Russian peptide used for immune problems, with negative cancer trials.

Also called: Timogen, Thymagen, L-Glu-L-Trp, Glu-Trp, EW, Alpha-glutamyl-tryptophan, Oglufanide, IM862, IM-862.

Khavinson bioregulator peptides · Synthetic L-glutamyl-L-tryptophan immune-modulating dipeptide.

Controlled IM862 cancer trials found no clear benefit. The 59 human records include trial registrations, incomplete reports and stomach studies that reuse participants.

Key studies

  • Kaposi sarcoma: two nasal schedules: Early responses were not confirmed in the later placebo-controlled trial. (source)
  • Kaposi sarcoma: negative phase 3: IM862 did not beat placebo and may have accelerated progression. (source)
  • Kidney cancer: no tumor responses: High nasal doses produced no objective cancer responses. (source)
  • Prostate cancer: no clear benefit: IM862 did not prolong time to PSA progression. (source)
  • Before abdominal cancer surgery: Fewer complications were reported, with important reporting errors. (source)
  • Skin and soft-tissue wound trial: A small blinded trial reported faster wound healing. (source)

Related to Thymogen

Sources

Sources checked: 2026-10-18.

Information only, not medical advice. Peptifacts does not sell anything and does not link to sellers.